medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2025, Number 1

<< Back Next >>

Acta Pediatr Mex 2025; 46 (1)

Comprehensive Review of the Effective Use of Fructooligosaccharides in the Health- Disease Process in Children

Montijo VAD, Rodríguez VCG, Fernández LC, Pacheco GS, Sanhueza CEA, García TI, López VG

Language: Spanish
References: 82
Page: 24-39
PDF size: 288.50 Kb.


ABSTRACT

Nowadays, health professionals specializing in children know that their prescription decisions on the use of probiotics must be based on the properties of selected microorganism strains. Scientific evidence generated over the last decades supports such decision-making. Prebiotics and postbiotics are other important players involved in the prescription of naturally occurring products; however, they have similar stories to those of probiotics. Inulin from chicory and fructans from agave plants are empowering their use in preventing and treating several diseases. Nevertheless, the published evidence shows that there are differences in the mechanism of action of these non-digestible carbohydrates depending on their source, structure, and physicochemical properties. Even though most studies demonstrate the beneficial effects of these fructans for human health, there exists controversy over their use in several pediatric conditions. Therefore, the main aim of this review is giving to health professionals specializing in children comprehensive, high-scientific quality, and updated evidence on the use of plant fructans to cope with several diseases of childhood.


REFERENCES

  1. Institute for Health Metrics and Evaluation (IHME). (2019).Estadísticas de defunciones registradas en México paraambos sexos. Available from: https://vizhub.healthdata.org/gbd-compare/#

  2. Hernández, C. C., Aguilera A. M. G., & Castro E. G. Gastrointestinaldiseases, situation in Mexico. EnfermedadesInfecciosas y Microbiología.2011; 31(4), 137-151.

  3. Cani, P. D., Knauf, C., Iglesias, M. A., Drucker, D. J., Delzenne,N. M., & Burcelin, R. Improvement of glucose toleranceand hepatic insulin sensitivity by oligofructose requiresa functional glucagon-like peptide 1 receptor. Diabetes,2006;55(5), 1484-1490.

  4. Włodarczyk M, Katarzyna Ś. Obesity as the 21st Century'smajor disease: The role of probiotics and prebiotics in preventionand treatment. Food Bioscience, 2021;42: 101115.

  5. y Abreu A A, Milke-García M P, Argüello-Arévalo G A,Calderón-de la Barca AM, Carmona-Sánchez RI, Consuelo-Sánchez A, et al. Dietary fiber and the microbiota: A narrativereview by a group of experts from the AsociaciónMexicana de Gastroenterología. Revista de Gastroenterologíade México (English Edition), 2021;86(3):287-304.

  6. Gill SK, Rossi M, Bajka B, Whelan K. Dietary fibre in gastrointestinalhealth and disease. Nature reviews. Gastroenterology& hepatology, 2021;18(2):101-116.

  7. Roberfroid M, Gibson GR, Hoyles L, McCartney AL, RastallR, Rowland I, Meheust A. Prebiotic effects: metabolic andhealth benefits. The British journal of nutrition, 2010;104(2):1-63.

  8. Weiss GA, Hennet T. Mechanisms and consequences ofintestinal dysbiosis. Cellular and molecular life sciences:CMLS, 2017;74(16):2959-2977.

  9. Álvarez-Hernández JC, Fernández-Real JM, Guarner F,Gueimondé M, Rodríguez JM, Saenz de Pipaon M, Sanz Y.Gut microbes and health. Gastroenterología y Hepatología,2021;44(7):519-535.

  10. Bevilacqua A, Campaniello D, Speranza B, Racioppo A,Sinigaglia M, Corbo M R. (2024). An Update on Prebioticsand on Their Health Effects. Foods, 2024:13(3): 446.

  11. Tsai YL, Lin TL, Chang CJ, Wu TR, Lai WF, Lu CC, Lai HC.Probiotics, prebiotics and amelioration of diseases. Journalof biomedical science, 2019;26(1):3.

  12. Lambertz J, Weiskirchen S, Landert S, Weiskirchen R. Fructose:A Dietary Sugar in Crosstalk with Microbiota Contributingto the Development and Progression of Non-AlcoholicLiver Disease. Frontiers in immunology, 2017;8:1159.

  13. He J, Zhang P, Shen L, Niu L, Tan Y, Chen L, et al. Short-ChainFatty Acids and Their Association with Signalling Pathwaysin Inflammation, Glucose and Lipid Metabolism. Internationaljournal of molecular sciences, 2020;2(17):6356.

  14. Nogal A, Valdés AM, Menni C. The role of short-chain fattyacids in the interplay between gut microbiota and diet incardio-metabolic health. Gut Microbes, 2021;13(1):1-24.

  15. Pérez-López AV, Simpson J. The Sweet Taste of Adapting tothe Desert: Fructan Metabolism in Agave Species. Frontiersin plant science, 2020;11:324.

  16. Márquez Guzmán J, Collazo Ortega M, Martínez GordilloM, Orozco Segovia A, Vázquez Santana S. Biología de Angiospermas.Las Prensas de Ciencias Editores, México DF,México, 2016:490-502

  17. Montañez-Soto J, Venegas-González J, Vivar-Vera M, Ramos-Ramírez E. Extracción, caracterización y cuantificaciónde los fructanos contenidos en la cabeza y en las hojas delAgave tequilana Weber azul. Bioagro, 2011;23(3): 199-206.

  18. Ulloa AJ, Andrews EH, Cruz RK, Ulloa RP, Rangel UE, RamírezRC. Los fructanos y su papel en la promoción de la salud.Revista Fuente, 2010;2(5): 57-62.

  19. Armas Ramos RA, Martínez García D, Pérez Cruz ER.Fructanos tipo inulina: efecto en la microbiota intestinal,la obesidad y la saciedad. Gaceta Médica Espirituana,

  20. 2019;21(2): 134-145.20. Chen G, Li C, Chen K. Chapter 6 - Fructooligosaccharides:A Review on Their Mechanisms of Action and Effects.Studies in Natural Products Chemistry (Elsevier), 2016;48:209-229.

  21. Costa GT, Vasconcelos JS, Aragão GF. Fructooligosaccharideson inflammation, immunomodulation, oxidativestress, and gut immune response: a systematic review.Nutrition Reviews, 2022;80(4): 709–722.

  22. Femitha P, Ghazi SA, Nayankumar RK, Ravishankar K, SamikH, Satyen KH, et al. Clinical Uses of Fructooligosaccharidesfor Gastrointestinal health in the Pediatric Population.Indian Journal of Child Health, 2022;9(12): 214-220.

  23. Wegh AM, Schoterman HC, Vaughan EE, Belzer C, BenningaMA. The effect of fiber and prebiotics on children’s gastrointestinaldisorders and microbiome. Expert Review ofGastroenterology & Hepatology, 2017;11(11): 1031–1045.

  24. De la Torre Mondragón L, Hernández VG. Constipacionintestinal funcional en pediatría. Acta pediátrica de México,2014;35(5): 411-422.

  25. Toporovski MS, de Morais MB, Abuhab A, Crippa JúniorMA. Effect of Polydextrose/Fructooligosaccharide Mixtureon Constipation Symptoms in Children Aged 4 to 8 Years.Nutrientes, 2021;13(5):1634.

  26. Souza DDS, Tahan S, Weber TK, Araujo-Filho HB, de MoraisMB. Randomized, Double-Blind, Placebo-ControlledParallel Clinical Trial Assessing the Effect of Fructooligosaccharidesin Infants with Constipation. Nutrients,2018;10(11): 1602.

  27. Moore N, Chao C, Yang LP, Storm H, Oliva-Hemker M, SaavedraJM. Effects of fructo-oligosaccharide-supplementedinfant cereal: a double-blind, randomized trial. The Britishjournal of nutrition, 2003;90(3): 581–587.

  28. López-Velázquez G, Díaz-García L, Anzo A, Parra-OrtizM, Llamosas-Gallardo B, Ortiz-Hernández AA, Mancilla-Ramírez J, Cruz-Rubio JM, Gutiérrez-Castrellón P. Safetyof a dual potential prebiotic system from Mexican agave"Metlin® and Metlos®", incorporated to an infant formulafor term newborn babies: a randomized controlled trial.Rev Invest Clin, 2013;65(6):483-90.

  29. Weber TK, Toporovski MS, Tahan S, Neufeld CB, de MoraisMB. Dietary fiber mixture in pediatric patients with controlledchronic constipation. Journal of pediatric gastroenterologyand nutrition, 2014;58(3): 297–302.

  30. Kumar S, Kelly AS. Review of Childhood Obesity: FromEpidemiology, Etiology, and Comorbidities to ClinicalAssessment and Treatment. Mayo Clinic proceedings,2017;92(2): 251–265.

  31. Murata C, Gutiérrez-Castrellón P, Pérez-Villatoro F, García-Torres I, Enríquez-Flores S, de la Mora-de la Mora I, etal. Delivery mode-associated gut microbiota in the first3 months of life in a country with high obesity rates: Adescriptive study. Medicine, 2020;99:40.

  32. Rizzatti G, Lopetuso LR, Gibiino G, Binda C, GasbarriniA. Proteobacteria: A common factor in human diseases.BioMed Res Int. 2017; 2017:9351507.

  33. Fei N, Zhao L. An opportunistic pathogen isolated from thegut of an obese human causes obesity in germfree mice.ISME J. 2013;7(4):880–884.

  34. Borka Balas R, Meliț LE, Lupu A, Lupu VV, Mărginean CO.Prebiotics, probiotics, and synbiotics-A research hotspotfor pediatric obesity. Microorganisms. 2023;11(11):2651.

  35. Padilla-Camberos E, Barragán-Álvarez CP, Díaz-Martínez NE,Rathod V, Flores-Fernández JM. Effects of agave fructans(Agave tequilana Weber var. azul) on body fat and serumlipids in obesity. Plant Foods Hum Nutr. 2018;73(1):34-39.

  36. Barbero-Becerra V, Juárez-Hernández E, Chávez-TapiaNC, Uribe M. Inulin as a clinical therapeutic interventionin metabolic associated fatty liver disease. Food Rev Int.2022;38(1):336–348.

  37. Nicolucci AC, Hume MP, Martinez I, Mayengbam S, WalterJ, Reimer RA. Prebiotics reduce body fat and alter intestinalmicrobiota in children who Are overweight or with obesity.Gastroenterology. 2017;153(3):711–722.

  38. Vega-Cárdenas M, Martínez-Gutiérrez F, Lara-Ramírez EE,et al. Agave fructans enhance the effects of fermented milkproducts on obesity biomarkers: a randomised trial. BenefMicrobes. 2023;14(2):153–164.

  39. López-Velázquez G, Parra-Ortiz M, Mora I de L, et al. Effectsof fructans from Mexican agave in newborns fed withinfant formula: a randomized controlled trial. nutrients.2015;7(11):8939-51.

  40. Hyams JS, Di Lorenzo C, Saps M, et al. Childhood functionalgastrointestinal disorders: Child/adolescent. Gastroenterology.2016;150(6):1456-1468.

  41. Canavan C, West J, Card T. The epidemiology of irritablebowel syndrome. Clin Epidemiol. 2014; 6:71-80.

  42. Shulman RJ, Hollister EB, Cain K, et al. Psyllium fiber reducesabdominal pain in children with irritable bowel syndrome ina randomized, double-blind trial. clin gastroenterol hepatol.2017;15(5):712–719.

  43. Sperber AD, Bangdiwala SI, Drossman DA, GhoshalUC, Simren M, Tack J, et al. Worldwide prevalence andburden of functional gastrointestinal disorders, resultsof Rome Foundation Global Study. Gastroenterology.2021;160(1):99-114.

  44. Romano C, Comito D, Famiani A, Calamarà S, Loddo I.Partially hydrolyzed guar gum in pediatric functional abdominalpain. World J Gastroenterol. 2013;19(2):235–240

  45. Chumpitazi BP, McMeans AR, Vaughan A, et al. Fructansexacerbate symptoms in a subset of children withirritable bowel syndrome. clin gastroenterol hepatol.2018;16(2):219-225.e1.

  46. Isakov V, Pilipenko V, Shakhovskaya A, Tutelyan V. Efficacyof inulin enriched yogurt on bowel habits in patients withirritable bowel syndrome with constipation: a pilot study.FASEB J. 2013; 27:2013 Issue 10.

  47. Welters CF, Heineman E, Thunnissen FB, van den BogaardAE, Soeters PB, Baeten CG. Effect of dietary inulin supplementationon inflammation of pouch mucosa in patientswith an ileal pouch-anal anastomosis. Dis Colon Rectum.2002;45(5):621-7.

  48. Casellas F, Borruel N, Torrejón A, Varela E, Antolín M,Guarner F, Malagelada JR. Oral oligofructose-enrichedinulin supplementation in acute ulcerative colitis is welltolerated and associated with lowered faecal calprotectin.Aliment Pharmacol Ther. 2007;25(9):1061-7.

  49. De Preter V, Joossens M, Ballet V, Shkedy Z, Rutgeerts P,Vermeire S, Verbeke K. Metabolic profiling of the impact ofoligofructose-enriched inulin in Crohn's disease patients:A double-blinded randomized controlled trial. Clin TranslGastroenterol. 2013;4(1): e32.

  50. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, RaymentN, et al. Clinical, microbiological, and immunologicaleffects of fructo-oligosaccharide in patients with Crohn'sdisease. Gut. 2006;55(3):348-55.

  51. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthyNE, Hart AL, et al. Randomised, double-blind, placebocontrolledtrial of fructo-oligosaccharides in active Crohn'sdisease. Gut. 2011;60(7):923-9.

  52. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. Adiet low in FODMAPs reduces symptoms of irritable bowelsyndrome. Gastroenterology. 2014;146(1):67-75. e5.

  53. Pérez N, Torres-López E, Zamarripa-Dorsey F. Respuestaclínica en pacientes mexicanos con síndrome de intestinoirritable tratados con dieta baja en carbohidratos fermentables(FODMAP). Rev Gastroenterol Mex. 2015;80(3):180-5.

  54. Bennet SMP, Böhn L, Störsrud S, Liljebo T, Collin L, LindforsP, et al. Multivariate modelling of faecal bacterial profilesof patients with IBS predicts responsiveness to a diet lowin FODMAPs. Gut. 2018;67(5):872-81.

  55. Moncada E, Bulut N, Li S, Johnson T, Hamaker B, Reddivari L.Dietary fiber's physicochemical properties and gut bacterialdysbiosis determine fiber metabolism in the gut. Nutrients.2024;16(15):2446.

  56. Alam MT, Amos GCA, Murphy ARJ, Murch S, WellingtonEMH, Arasaradnam RP. Microbial imbalance in inflammatorybowel disease patients at different taxonomic levels.Gut Pathog. 2020; 12:1.

  57. Ghoshal UC, Shukla R, Ghoshal U. Small intestinalbacterial overgrowth and irritable bowel syndrome: abridge between functional organic dichotomy. Gut Liver.2017;11(2):196-208.

  58. Alcedo J, Estremera-Arévalo F, Cobián J, Santos J, Alcalá LG,Naves J, et al. Preguntas comunes y respuestas razonadassobre el síndrome del sobrecrecimiento bacteriano intestinal(SIBO). Gastroenterol Hepatol. 2024;502216.

  59. Saffouri GB, Shields-Cutler RR, Chen J, Yang Y, Lekatz HR,Hale VL, et al. Small intestinal microbial dysbiosis underliessymptoms associated with functional gastrointestinaldisorders. Nat Commun. 2019;10(1):2012.

  60. Abreu AT, Milke-García MP, Argüello-Arévalo GA, Calderóndela Barca AM, Carmona-Sánchez RI, Consuelo-Sánchez A,et al. Fibra dietaria y microbiota, revisión narrativa de ungrupo de expertos de la Asociación Mexicana de Gastroenterología.Rev Gastroenterol Mex. 2021;86(3):287-304.

  61. Healey GR, Celiberto LS, Lee SM, Jacobson K. Fiber andprebiotic interventions in pediatric inflammatory boweldisease: what role does the gut microbiome play? Nutrients.2020;12(10):3204.

  62. Olesen M, Gudmand-Hoyer E. Efficacy, safety, and tolerabilityof fructooligosaccharides in the treatment of irritablebowel syndrome. Am J Clin Nutr. 2000;72(6):1570-5.

  63. Fernández-Lainez C, López-Velázquez G, De Vos P. Healthbenefits of inulin and agavin-type fructans in food: Impacton microbiota, immune and gut barrier function. In: Thebook of fructans. Academic Press; 2023. p. 211-34.

  64. Kanneganti TD. Intracellular innate immune receptors: Lifeinside the cell. Immunol Rev. 2020;297(1):5–12.

  65. Lebeer S, Vanderleyden J, De Keersmaecker SC. Hostinteractions of probiotic bacterial surface molecules:comparison with commensals and pathogens. Nat RevMicrobiol. 2010;8(3):171–184.

  66. Punt J, Stranford SA, Jones PP, Rivera Muñoz B, Owen JA.Kuby inmunología. 8th ed. McGraw-Hill Interamericana;2020.

  67. Abreu MT. Toll-like receptor signalling in the intestinalepithelium: how bacterial recognition shapes intestinalfunction. Nat Rev Immunol. 2010;10(2):131–144.

  68. Bernardo D. Human intestinal dendritic cells as controllersof mucosal immunity. Rev Esp Enferm Dig.2013;105(5):279-290.

  69. Vásquez Cachay M, Vega Acosta H. Development of theepithelium of the intestinal tract and its participation inthe defense of the organism in mammals. Rev ElectronVet. 2012;13(7):1-40.

  70. Vinderola G, Matar C, Perdigon G. Role of intestinal epithelialcells in immune effects mediated by gram-positiveprobiotic bacteria: Involvement of toll-like receptors. ClinDiagn Lab Immunol. 2005;12(9):1075–1084.

  71. Vogt L, Ramasamy U, Meyer D, et al. Immune modulationby different types of β2→1-fructans is toll-like receptordependent. PLoS One. 2013;8(7)

  72. Peshev D, Van den Ende W. Fructans: Prebiotics and immunomodulators.J Funct Foods. 2015; 8:1-42.

  73. Pujari R, Banerjee G. Impact of prebiotics on immuneresponse: from the bench to the clinic. Immunol Cell Biol.2021;99(3):255–273.

  74. Bermudez-Brito M, Faas MM, de Vos P. Modulation ofdendritic-epithelial cell responses against Sphingomonaspaucimobilis by dietary fibers. sci rep. 2016; 6:30277

  75. Moreno-Vilet L, García-Hernández MH, Delgado-PortalesRE, et al. In vitro assessment of agave fructans (Agavesalmiana) as prebiotics and immune system activators. IntJ Biol Macromol. 2014; 63: 181–187.

  76. Fernández-Lainez C, Akkerman R, Oerlemans MMP, et al. β(2→6)-Type fructans attenuate proinflammatory responsesin a structure dependent fashion via Toll-like receptors.Carbohydr Polym. 2022; 277:118893.

  77. Verma DK, Patel AR, Thakur M, et al. A review of the compositionand toxicology of fructans, and their applicationsin foods and health. J Food Compos Anal. 2021; 99:103884.

  78. Roberfroid MB. Inulin-type fructans: functional food ingredients.J Nutr. 2007;137(11):2493S–2502S.

  79. Vijn I, Smeekens S. Fructan: More Than a Reserve Carbohydrate?Plant Physiol. 1999;120(2):351–360.

  80. López MG, Mancilla-Margalli NA, Mendoza-Diaz G. Molecularstructures of fructans from Agave tequilana Weber var.azul. J Agric Food Chem. 2003;51(27):7835–7840.

  81. Praznik W, Löppert R, Cruz Rubio JM, Zangger K, HuberA. Structure of fructo-oligosaccharides from leaves andstem of Agave tequilana Weber, var. azul. Carbohydr Res.2013; 381:64–73.

  82. Ito H, Takemura N, Sonoyama K, et al. Degree of polymerizationof inulin-type fructans differentially affects numberof lactic acid bacteria, intestinal immune functions, andimmunoglobulin A secretion in the rat cecum. J Agric FoodChem. 2011;59(10):5771–5778.




2020     |     www.medigraphic.com